RFK Jr. Opens the Door to Six Peptides: What the New U.S. Policy Means for Research
*A significant shift in American peptide policy is taking shape.*
On October 28, the U.S. Department of Health and Human Services (HHS), led by Secretary Robert F. Kennedy Jr., released an interim enforcement-discretion policy addressing BPC-157, TB-500, epitalon, KPV, MOTS-c and Semax. A notice published in the Federal Register on October 30 describes the policy document as a draft and invites public comment.
The policy outlines a conditional pathway for certain pharmacies and licensed physicians to compound these substances for individual patients while FDA rulemaking continues.
For the U.S. research community, the distinction matters, but a change in compounding enforcement does not turn research-use-only materials into approved medicines or authorize their sale for human use.
What does the policy change?
HHS states that it does not intend to take enforcement action against qualifying state-licensed pharmacies, federal facilities, or licensed physicians compounding specified peptide substances when the policy’s conditions are met. The approach concerns Section 503A of the Federal Food, Drug, and Cosmetic Act.
Those conditions include valid patient-specific prescriptions, defined chemical identities, ingredient sourcing from appropriately registered manufacturers, manufacturing-quality requirements, certificates of analysis, labeling and reporting of serious adverse events and product-quality issues. The policy also specifies compound-dependent limitations on routes of administration.
Each compounded product must contain only a single active pharmaceutical ingredient listed in the policy. This provision is intended to make safety monitoring and attribution more meaningful; it should not be described as a blanket ban on all combinations in every context.
The policy does not provide FDA approval. Compounded drugs are not FDA-approved, and enforcement discretion does not establish that these six substances are safe or effective for particular medical uses.
The six peptides and the research behind them
The substances covered by the policy have attracted interest across several areas of biological research:
BPC-157: tissue-repair processes, gastrointestinal biology and cellular responses to injury. TB-500: biological processes associated with tissue repair and cell migration. Precise identity matters: the policy specifies a particular peptide fragment, rather than treating every thymosin-related product as interchangeable. Epitalon: cellular aging, telomere biology and circadian-related research. KPV: inflammatory signaling and epithelial biology. MOTS-c: mitochondrial signaling and metabolic regulation. Semax: neurological signaling and neuroprotection research.
These descriptions identify research topics, not established treatment benefits. Evidence differs by compound, experimental model and formulation. Findings from cells, animals or related molecules cannot automatically establish clinical outcomes for the specific substance under discussion.
Why is HHS pursuing this approach?
HHS argues that some Americans are already obtaining research-use-only peptides for personal use through poorly controlled supply chains. The agency presents conditional prescription compounding as a more accountable alternative, with requirements for ingredient documentation, manufacturing standards, testing and safety reporting.
That rationale should be read carefully. It addresses a proposed medical-access framework; it does not endorse the personal use of research materials or certify individual research suppliers.
The underlying scientific debate also remains unresolved. The HHS document records differences between FDA scientific staff assessments and Pharmacy Compounding Advisory Committee recommendations. Committee votes inform the regulatory process, but they do not constitute drug approvals.
What does this mean for research-use-only peptide distributors?
For a U.S. research supplier, the central responsibility remains clear communication about what a product is and its intended use.
USA Peptide Depot supplies materials for laboratory research. Its research products are not prescription medications and are not intended for human or veterinary use. The new policy does not change that positioning.
Nor does it mean that an ordinary research vial qualifies as a bulk drug substance for prescription compounding. The policy sets specific expectations for the original manufacturer, chemical identity, documentation and quality controls. A research-use-only label or a purity report alone does not establish that those expectations have been met.
Legitimate laboratory supply, patient-specific compounding, and FDA-approved medicines serve different purposes and operate under different requirements. Clear distinctions help researchers evaluate suppliers and prevent regulatory news from becoming misleading marketing.
Why analytical verification matters
Reliable experiments depend on well-characterized materials. Incorrect identity, unexpected impurities or inconsistent composition can compromise results and make findings difficult to reproduce.
That is why independent testing and lot-specific documentation matter. Researchers should be able to match a report to the material they received, identify the analytical method and understand what was actually measured.
HPLC can provide information about chromatographic purity under a defined method. Other methods may be needed to assess identity, quantity, residual solvents, microbial contamination, endotoxins or other characteristics. A single purity percentage should not be treated as an answer to every quality question.
Analytical testing also has limits. It cannot establish effective human dosing, long-term safety or therapeutic benefit. A COA supports conclusions only about the sample, methods and measurements it documents.
At USA Peptide Depot, we applaud the emphasis the proposed policy places on testing and transparency. It reflects our emphasis on independent HPLC testing, available lot-specific documentation, and our commitment to transparency. Researchers should review the documentation available for the specific product and lot, including its scope and limitations.
Don’t Trust. Verify.
What’s next?
The October 30 Federal Register notice opens a public-comment period ending November 13, 2026. It describes the policy as a draft and states that it is nonbinding and does not establish rights for any person.
Future FDA rulemaking may propose adding some or all of the substances to the formal Section 503A bulk-substances list. HHS also says it may revisit the interim policy if safety signals or product-quality concerns arise.
For now, researchers and suppliers should still follow the current rules rather than assume that this announcement permanently settles the status of any compound.
Evidence remains the standard
This development brings greater attention to peptide science and to the importance of documented ingredients, quality controls and accountability. Those priorities deserve attention across the industry.
The policy does not validate every peptide, product or supplier. It reinforces the need to distinguish what analytical testing can demonstrate from what clinical research has yet to establish.
USA Peptide Depot’s role remains supplying research materials with clear intended-use boundaries, accessible documentation where available, and straightforward communication. As the regulatory conversation evolves, our standard remains the same:
Don’t Trust. Verify.
Editorial disclosure: This article provides scientific and regulatory information, not medical advice or a recommendation to use unapproved substances. USA Peptide Depot products are intended exclusively for laboratory research and are not for human or veterinary use.
Sources and further reading
HHS enforcement-discretion policy and peptide-specific appendices
Federal Register notice, October 30, 2026 — Docket HHS-OASH-2026-0496